MenASCLEPIUSNCT04295057
Register of Therapeutical Patients Over 60 Years
An observational study of Men and Age Problem, run by Eurasian Association of Therapists at 1 site in Russia.
Trial summary
Register for the study of the prevalence and burden of diseases, risk factors and outcomes of hospitalizations in older age groups in the countries of Eurasia. Read more about this study
- Who is it for?
- Ages 60 years and olderHealthy volunteers can take part
- Conditions the study is for
- Men, Age Problem, Therapeutic Alliance
- What is being tested?
- Non-intervention
- How many people
- 12,000 participants
- Where
- 1 siteRussia
- Study dates
- 15 Jan 2023to 15 Mar 2024
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Anonymous men and women in the age group over 60 see a doctor for any reason.
Who may be able to join
- over 60 years
- Appointment to a doctor of a therapeutic profile
Who cannot join
- Reluctance of the Patient to participate in the Register;
- Age under 60 at the time of inclusion in the Register.
Trial locations and contacts
1 site in 1 country.
Russia1 site
Eurasian Association of Therapists
Moscow, 101000
Tamara Kriukova, +79992114977, tk@euat.ru
Anastasia Rud, +79263639827, rud@euat.ru
About this study
Official title: Register on the Study of Prevalence and Incidence, Risk Factors and Outcomes of Hospitalizations in Older Age Groups in Eurasia.
Register for the study of the prevalence and burden of diseases, risk factors and outcomes of hospitalizations in older age groups in the countries of Eurasia.
Read the detailed description
An open, multicenter registry to track all major noncommunicable diseases and risk factors in older age groups, prescribed drugs, and disease outcomes.
- Conditions
- Men, Age Problem, Therapeutic Alliance
- Being tested
- Non-intervention
- Keywords
- register, therapy
- Medical subject headings
- Multiple Endocrine Neoplasia Type 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-interventionOther
Non-intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence
Incidence of non-infectious diseases
Measured: 12 months
Non-infectious diseases
Age-related non-infectious diseases dynamics of the development of the main after 60 years
Measured: 12 months
Age groups
The prevalence of various non-infectious diseases in different age groups
Measured: 12 months
Therapy
Names, doses and duration of prescribed therapy
Measured: 12 months
Drugs
Analysis of prescribed therapy and calculation of losses from improper treatment due to repeated hospitalizations, disability and complications
Measured: 12 months
Measure criteria
12000 patients
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2020
- Study start15 Jan 2023 (estimated)
- Primary completion15 Mar 2024 (estimated)
- Study completion15 Mar 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MenStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 12,000 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Eurasian Association of Therapists
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tamara Kriukova, Eurasian Association of Therapists
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04295057
- Sponsor's protocol ID
- EUAT
- Other IDs
- ASCLEPIUS
- Acronym
- ASCLEPIUS
- Status last verified
- Feb 2022
- First submitted
- 3 Mar 2020
- Last updated
- 2 Feb 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Register on the Study of Prevalence and Incidence, Risk Factors and Outcomes of Hospitalizations in Older Age Groups in Eurasia.
- ClinicalTrials.gov ID
- NCT04295057
- Acronym / sponsor ID
- ASCLEPIUS / EUAT
- Conditions
- Men, Age Problem, Therapeutic Alliance
- Keywords
- register, therapy
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 12,000 participants (estimated)
- Lead sponsor
- Eurasian Association of TherapistsUniversity, hospital or other
- Study start
- 15 Jan 2023 (estimated)
- Primary completion
- 15 Mar 2024 (estimated)
- Study completion
- 15 Mar 2024 (estimated)
- First posted
- 4 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Register for the study of the prevalence and burden of diseases, risk factors and outcomes of hospitalizations in older age groups in the countries of Eurasia.
Detailed description
An open, multicenter registry to track all major noncommunicable diseases and risk factors in older age groups, prescribed drugs, and disease outcomes.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 12 Months
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Anonymous men and women in the age group over 60 see a doctor for any reason.
Key inclusion criteria (2 listed)
- over 60 years
- Appointment to a doctor of a therapeutic profile
Key exclusion criteria (2 listed)
- Reluctance of the Patient to participate in the Register;
- Age under 60 at the time of inclusion in the Register.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-interventionNon-intervention | Other | – |
Primary outcome
Incidence
Time frame: 12 months
Incidence of non-infectious diseases
Non-infectious diseases
Time frame: 12 months
Age-related non-infectious diseases dynamics of the development of the main after 60 years
Age groups
Time frame: 12 months
The prevalence of various non-infectious diseases in different age groups
Therapy
Time frame: 12 months
Names, doses and duration of prescribed therapy
Drugs
Time frame: 12 months
Analysis of prescribed therapy and calculation of losses from improper treatment due to repeated hospitalizations, disability and complications
Measure criteria
Time frame: 12 months
12000 patients
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2022.
- Individual participant dataSharing planned: No
Related trials for Men
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Active, not recruitingPhase 2/3
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
Urinary Incontinence, Overactive Bladder Syndrome
Not yet recruitingPhase 2
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
Insulin Resistance, Obesity
RecruitingObservational study
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Prostate Cancer, Prostate Adenocarcinoma
RecruitingObservational study
Anticipated Stigma, Illness Identity, and Quality of Life in Male Hypogonadism
Hypogonadism, Male, Endocrine Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Men and Age Problem, run by Eurasian Association of Therapists at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Alexandra Deeva (+79033777940, adeeva@euat.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence (time frame: 12 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2022.